KIROMIC BIOPHARMA INC (KRBP) Stock News

Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival

Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01

Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01

KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024

Kiromic BioPharma just reported results for the second quarter of 2024.

KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kiromic BioPharma (NASDAQ:KRBP) just reported results for the first quarter of ...

KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024

Kiromic BioPharma just reported results for the first quarter of 2024.

Financial Crime Weekly: CEO Sentenced To 51 Months In Prison, Kiromic BioPharma Charged With Failure To Disclose Material Information

A CEO is sentenced to 51 months in prison for fraud and ordered to pay $6.1 million in restitution. Kiromic BioPharma is charged with failure to disclose material information.

Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation

Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01

Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial

Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation

Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation

Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial

Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01

Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase

Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial

Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial

Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site

Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Mentions: LSTA SYRA ACHV MRDH

Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Mentions: LSTA SYRA ACHV

Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th

Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th

Live and Archived Fireside Chat Available at VirtualInvestorConferences.com

Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

Kiromic BioPharma Announces Uplisting to OTCQB Market

Mentions: OTC

Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center

Mentions: OTC

Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement

Mentions: OTC

12 Health Care Stocks Moving In Wednesday's After-Market Session

Mentions: INFI SCNI NSTG JYNT ...

Kiromic BioPharma to list on OTC Pink Sheets after Nasdaq trading suspension (NASDAQ:KRBP)

Kiromic BioPharma (KRBP) Wednesday said it received a formal notice that its common stock was suspended from trading on the Nasdaq Capital Market.Subsequently, the company added that...

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14